May 11, 2021 Via Email Only Han Myint, M.D. RE:EXECUTIVE EMPLOYMENT AGREEMENT Dear Dr. Myint: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure...Executive Employment Agreement • March 3rd, 2022 • NextCure, Inc. • Pharmaceutical preparations • Maryland
This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***]. SECOND AMENDMENT TO LICENSE...License Agreement • March 3rd, 2022 • NextCure, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LICENSE AGREEMENT AND SRA (this “AMENDMENT”) is made and entered into, and effective, as of this 20th day of October 2021 (the “AMENDMENT EFFECTIVE DATE”) by and between Yale University, a nonprofit corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut (“YALE”), and NextCure, Inc., a corporation organized and existing under the laws of the State of Delaware (“LICENSEE”). YALE and LICENSEE are each referred to herein, individually, as a “party” and, collectively, as the “parties.”
